CD8A and retinopathy of prematurity: Our finding demonstrated AVR-123’s efficacy in reducing multiple splenic immune cell types, such as macrophages, neutrophils, dendritic cells, and cytotoxic CD8+ T cells, implicated in ROP pathology.